| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3431c45beae45fc561cbc89bf740034e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8a3bb71cfa6445c719dc4eaa66d8fce |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36 |
| filingDate |
2011-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c14db879f57d8a00b2554b8dc5df8ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_779f4203603db9b5fd22e602b747071e |
| publicationDate |
2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101119587-B1 |
| titleOfInvention |
Oral Dosage Formulations with Improved Elution Rate and Stability Containing Sarbic Oxide |
| abstract |
The present invention relates to oral formulations containing arsenic hexaoxide which have improved dissolution rate and stability. The formulation for oral administration of the present invention can improve the dissolution rate and stability of arsenic hexaoxide, thereby achieving a rapid effect, and thus can be usefully used as a formulation for oral administration due to its excellent bioavailability. Oral administration formulation of the present invention to express the optimal pharmacological clinical effect ensured safety oral cancer treatment, characterized in that the administration of 15 to 45mg 1-6 times a day divided by the patient on the basis of arsenic arsenide It provides a pharmaceutical formulation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10493100-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018088682-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018093029-A1 |
| priorityDate |
2011-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |